Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on March 9, 2015. The report discloses a material change in the employment agreement of the Company's Chief Executive Officer, Mark Weinreb.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes
The primary material change is the extension of CEO Mark Weinreb's employment agreement:
- Term Extension: The agreement term was extended from October 4, 2015, to December 31, 2017.
- Base Salary: Remains at $400,000 annually.
- 2015 Bonus: Entitled to an annual bonus equal to 50% of base salary ($200,000).
- 2016-2017 Bonus: Entitled to an annual bonus equal to 50% of base salary contingent on performance goals set by the Compensation Committee.
Outlook, Risks, and Contingencies
The filing outlines specific severance contingencies triggered by termination without "cause," termination for "good reason," or a change in control:
- Standard Termination: Severance equals one times annual base salary plus $100,000 (in lieu of bonus) and certain benefits. This also applies if the agreement is not extended beyond 2017 and employment is terminated within three months of expiration.
- Change in Control Termination: Severance equals one and one-half times annual base salary plus $300,000 (in lieu of bonus) and certain benefits.
Investor Verification Checklist
- Verify the specific performance goals required for the 2016 and 2017 bonuses as determined by the Compensation Committee.
- Review the definitions of "cause" and "good reason" within the full employment agreement to understand termination triggers.
- Confirm the Company's current cash position to assess its ability to fund potential severance obligations.
- Check for any subsequent filings regarding the extension or modification of this agreement.